Antimicrobial Resistance (AMR)
The WHO lists AMR in the top 10 global health threats but new antibiotic development is not keeping pace with the emergence of resistant pathogens. Novel ways to structure the market are being explored which incentivise developers and give healthcare systems new tools to fight AMR.
Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?
8 November 2023
NHS England conducted a public consultation on a ‘volume-delinked model’ subscription approach to address the market failure hindering the development of urgently needed antibiotics.
Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective
2 November 2023
New antibiotics are urgently needed, but their development is hindered by market failure. A ‘volume-delinked model’ subscription approach has been suggested to overcome this market failure, providing compensation regardless of sales volume.
New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
25 May 2023
The EU Commission has set out important but controversial proposals for an AMR pull incentive for new antibiotics. In the first of this insight series, we set out seven objectives an EU fit-for-purpose pull incentive should work to achieve.
A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance
19 May 2023
In this report, we propose a novel payment model that will incentivise broader value demonstration for diagnostics for antibiotics that could inform longer-term financing and reimbursement arrangements and guide prescribing behaviours.
Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
30 March 2023
In this report, we describe the design of a globally aligned, value-based, fully-delinked pull incentive, where payers provide manufacturers with a pre-specified subscription fee based on the value of the antibiotic, regardless of the volume used.
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
Programs to incentivise antibiotic R&D are underway in the UK and under consideration in the US, EU, Canada, and Japan. We have assessed the benefits and costs to the members of the G7/EU and project that all G7/EU members would see big payoffs ranging from 11:1 in the UK to 28:1 for the US and Japan. Global returns from reducing the 1.27m people dying each year from AMR are even higher.
The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off
16 November 2022
A Center for Global Development (CGD) paper authored by OHE’s Adrian Towse and CGD’s Rachel Silverman Bonnifield shows a very high expected return on investment (ROI)…
Can we “Netflix” the Broken Antibiotics Market?
23 September 2022
Building on the learnings from the NICE and NHS England pilot with a subscription-style approach to purchasing and evaluating antibiotics.
How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.
26 March 2020
This presentation to the Australian Society for Antimicrobials (ASA) meeting in Melbourne, on 27th February 2020 draws on OHE research, funded by the Wellcome Trust, on…